Cargando…
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma
Hepatocellular cancer (HCC) is currently the third leading cause of cancer death worldwide. The prognosis of patients diagnosed with late-stage disease is dismal due to high resistance to conventional systemic therapies. The introduction of sorafenib, despite its limited efficacy, as the standard sy...
Autores principales: | Coleman, Stacey J, Grose, Richard P, Kocher, Hemant M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918266/ https://www.ncbi.nlm.nih.gov/pubmed/27508175 http://dx.doi.org/10.2147/JHC.S48958 |
Ejemplares similares
-
Emerging Roles of Fibroblast Growth Factor 10 in Cancer
por: Clayton, Natasha S., et al.
Publicado: (2018) -
The Obscure Potential of AHNAK2
por: Zardab, Mohamed, et al.
Publicado: (2022) -
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015) -
Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion
por: Coleman, Stacey J, et al.
Publicado: (2014) -
Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
por: Wang, Haijun, et al.
Publicado: (2021)